Main Article Content
Coronavirus Disease 2019 (COVID-19) is an infectious viral disease caused by the severe acute respiratory syndrome coronavirus-2 or what is known as SARS-CoV-2. This virus is known to attack the respiratory tract, but recent studies showed that it is known to cause multiorgan damage causing morbidities and mortalites worldwide. Although the COVID-19 mortality rate is known to be related to lung organs damage, various studies have shown damage to the cardiovascular system, in the form of coagulopathy. The mechanism of coagulopathy in COVID-19 patients is not the same as the disease in general and it is still not known with certainty. However, recent studies have shown benefits of using anticoagulant therapy to COVID-19 patients. This review article aims to discuss the pathophysiology of coagulopathy in COVID-19 patients, the hypercoagulability state in COVID-19 patients and the role and management of anticoagulant therapy. Through this review article, it is hoped that the use of anticoagulants in COVID-19 patients can be understood and applied in the management of patients with COVID-19 to reduce morbidity and mortality in Indonesia.